九芝堂(000989.SZ):2020年淨利升41.72%至2.72億元 擬10派4元
格隆匯3月19日丨九芝堂(000989.SZ)披露2020年年度報吿,實現營業收入35.6億元,同比增長11.81%;歸屬於上市公司股東的淨利潤2.72億元,同比增長41.72%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2.5億元,同比增長62.79%;基本每股收益0.3242元,擬向全體股東每10股派發現金紅利4元(含税)。
報吿期內,公司6個產品品種實現銷售收入過億元,分別為疏血通注射液、六味地黃丸、驢膠補血顆粒、阿膠、安宮牛黃丸、足光散,其中安宮牛黃丸銷售收入同比增長44%,疏血通注射液銷售收入同比增長14.54%;23個產品品種實現銷售收入過千萬元,其中逍遙丸、歸脾丸、杞菊地黃丸、知柏地黃丸、桂附地黃丸等產品銷售收入同比均增長20%以上。
同時,公司緊跟行業發展趨勢,加強政策法規的研究解讀,快速推動創新業務穩步發展。創新研發板塊聚焦新藥研發、中藥再評價及健康產品研發工作,持續提升創新動能;穩步進軍再生醫學領域,深入開展幹細胞業務;健康服務板塊積極探索互聯網醫院業務發展模式;健康產品經營板塊以研發為戰略引領,初步擬定大健康產品規劃,發展方向及發展定位,經營模式逐步清晰。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.